1
10
20
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/17a975a461e654bd6cce863fd95c3b2d.pdf?Expires=1712793600&Signature=LF3DboDRnSYDZ3MOPZscYpZSFJ8W7fGfnP8Tl-8OlFkL7vmke0hVRHB4ymO7UiIYIn5GOQdzOv5KWIsWkQ2XWJhLtlaJwQivrTTRYWCL9RwWe4Ipqlk6wY4bwyFGdHYBj6Cin-wmXeylzGlcDjuykgvxGYeBTamz%7Ehw2RmOdm-OMnTG1A51fcErkf-g%7Ewwz8Mr9gu%7E1q6EJhHuSkqsaVh3IPSj9cCHmgvZmaoMQx1e3PLo8gqRIWUUjNfkfbNZmxGf1h%7EV8UsoNMFkET1Y3mdCanMmthDEZtkpZmxVLl9WTTLURfGKz%7EfCyDDzEwhqpfZG%7EyBq0-mjKlP0mIDMIwKg__&Key-Pair-Id=K6UGZS9ZTDSZM
bc07c610df4b143771042530a4e856c6
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The Potential Health Benefits of the Consciousness Energy Treated Novel Test Formulation on Various Functional Enzyme Biomarkers
Subject
The topic of the resource
Health & Wellness
Description
An account of the resource
The study objective was to investigate the effect of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in six different cells. The Biofield Energy Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 115.6% and 53.3% restoration of viable cells at 10 and 25 μg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UTMed + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 101.1%, 829.8% and 698.9% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 μg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 97.9% and 69.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 μg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 67.4% (at 0.1 μg/mL), 80.4% (at 0.1 μg/mL) and 119.8% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.6% and 82.5% in the BT-Med + UT-TI group at 25 and 63 μg/mL, respectively; while 123.9% at 10 μg/mL in the BT-Med + BT-TI group compared to untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 53.6% and 59% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 10 μg/mL compared to the untreated. Serotonin level was significantly increased by 85.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups at 0.1 μg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 245.9% and 211.5% at 10 and 50 μg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 μg/mL) in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs and brain functional enzymes biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones.Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, emphysema, chronic bronchitis, asthma, osteoporosis, cystic fibrosis, etc.
Creator
An entity primarily responsible for making the resource
Shirley Theresa Holmlund, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal and Snehasis Jana
Source
A related resource from which the described resource is derived
<a href="http://www.scitcentral.com/article.php?journal=26&article=811">http://www.scitcentral.com/article.php?journal=26&article=811</a>
Publisher
An entity responsible for making the resource available
Scitcentral
Date
A point or period of time associated with an event in the lifecycle of the resource
05 April 2020
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/cb8a7f7faa19cde6b764e6fa207929b4.pdf?Expires=1712793600&Signature=GlLrVs2dDsdjX%7ELeDP8JxNLoPhw4T%7EPLiJOA4bfs8OsxBQhQRvaA8TNnZlbSLOvwQot8Z5hgGszLLp1GgENCVifbtL1QMUDJwqWB3oGnbsHg%7ELREvaXus4r6QGCFyjLDoLIjvKqeKX5k6pHuZLWcV36mlxXCHeuVqJHo-OHmbBrlt2dVI3%7EQyX4h3Zy1Zag5pGIBozGspf2pvfLevyOrva1zN8g28ZTo9y-6QlmhO8c9M07x8wEWEqmirwy%7ExT0hHES%7EGjp07NjV36DycKyVXHwY2p%7Ejz2XCvMo6oKA1bpnJLaye3PzMyyljKaLCK5IG6subEWhWNaGSwUOqxK5rEQ__&Key-Pair-Id=K6UGZS9ZTDSZM
a3991110abe40f2ba344aee4f549e447
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/effect-of-the-biofield-energy-treated-test-formulation-on-tissue-specific-biomarkers-in-various-human-cells/">https://www.trivedieffect.com/science/effect-of-the-biofield-energy-treated-test-formulation-on-tissue-specific-biomarkers-in-various-human-cells/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Effect of the Biofield Energy Treated Test Formulation on Tissue Specific Biomarkers in Various Human Cells
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Dysfunction of vital organs are the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain, and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Jagdish Singh, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI showed 190.5%, 56.3%, and 73.8% restoration of cell viability at 1µg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, BT-Med + UT-TI and BT-Med + BT-TI groups showed 98.8% and 79.1% restoration of cell viability at 10µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 261.7%, 165.8%, and 167.8% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 1, and 10µg/mL, respectively compared to untreated. Alkaline phosphatase (ALP) level was significantly increased by 52.5% and 66.1% in the BT-Med + UT-TI group at 10 and 50µg/mL, respectively in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by101% and 170.6%in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 50µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 191.8% (at 0.01µg/mL) and 141.8% (10µg/mL)in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 88.1% (at 1µg/mL) and 44.9% (at 63µg/mL) in the BT-Med + UT-TI and UT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 19.6% and 13.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 25µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 475.6% (at 0.1µg/mL), 311.9% (at 1µg/mL), 400.5% (at 10µg/mL) and 250.9% (at 63µg/mL) in the BT-Med + BT-TI group compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 185% and 285.8% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10µg/mL compared to the untreated in MG-63 cells. Utterly, these results suggest that Biofield Energy Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Jagdish Singh, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Source
A related resource from which the described resource is derived
<a href="https://smjournals.com/pharmacology/fulltext/smjpt-v5-1021.php">https://smjournals.com/pharmacology/fulltext/smjpt-v5-1021.php</a>
Publisher
An entity responsible for making the resource available
SMGroup
Date
A point or period of time associated with an event in the lifecycle of the resource
Jul 03, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Bone Health
Brain health
Cardiac health
Consciousness Energy Healing
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/e6b9a4431ced2eb364749e0de05900d6.pdf?Expires=1712793600&Signature=h9NhTpKot9evzz5-cIvUIZC5QsaSRPUNNNcsXF%7EvneManq%7E-vNccLBSdoYVJsP0u8Ex9BOFP54EYSVJhpdMY1JnihnGGkD7S4S6iytZFiYC9usEaW88je0fjy4qcmsnyZ2JyeHWxjp1rsHrSzusvdEgAfiqskcP6Rqvp9EkOWvhRv9wbH5fWo0Al-Ut6QKkxj1NaTSpD4rPUHXM1sBLqboaB6OdHjeSF1No40OQT84x-2sEW7k2LieX-MErUEZoRv1JmLbj7vXSLpUQkqCg%7EscJcJpz5vr49E12x6RFA7Mz6i%7Ey-lHt0Fo9SU5kchAZ0CO9pdkH3oMtY7x3Ci%7EAhEQ__&Key-Pair-Id=K6UGZS9ZTDSZM
37d6527df7d373530896fe9cc02ece18
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/influence-of-the-biofield-energy-treated-novel-test-formulation-on-different-organ-specific-biomarkers/">https://www.trivedieffect.com/science/influence-of-the-biofield-energy-treated-novel-test-formulation-on-different-organ-specific-biomarkers/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Influence of the Biofield Energy Treated Novel Test Formulation on Different Organ Specific Biomarkers
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">The study aimed to evaluate the effect of the Biofield Energy Treated test formulation on the function of different vital organs viz. bones, heart, liver, lungs, and brain in multiple cell-based assays. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Lauree Ann Duprey-Reed, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI groups showed 81.1% (at 1µg/mL), 78.4% (at 63µg/mL), and 87.9% (at 63µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med+ BT-TI group showed 80.4% and 89.9% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 181.3%, 93.2%, and 90.7% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 25, and 63 µg/mL, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 102.6%, 80.5%, and 100.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 40% (at 10µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 156.2%, 80.1%, and 137.0% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1µg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.1% and 105.0% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 25 µg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 30.4% and 51.9% in the BT-Med + BT-TI group at 30 and 63 µg/mL, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 67.9% and 42.3% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1µg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL compared to the untreated in MG-63 cells. Overall, the study outcomes suggest that the Biofield Energy Treated novel proprietary test formulation significantly improved the vital functional enzyme biomarkers relevant to bones, heart, liver, lungs, and brain. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Lauree Ann Duprey-Reed, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Publisher
An entity responsible for making the resource available
Chembio Publishers
Date
A point or period of time associated with an event in the lifecycle of the resource
July 19, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/4cdaa0a5624c5f31f05b846dd7b8e453.pdf?Expires=1712793600&Signature=fxdEWOPIfyE5rVk93jFj726tOhEv2PCuhA6K2caPVxqS1wBLZpTQerM9GUgLj3C-QCA8GLVMArvctf54GYtbyLtcG9p-44DNkrT3vHhqzGGk17l1MePDSJ407P7Ayo2RfZwYw%7E659vcmt69O1A0LpZfflnrac5lxxWCklTqWutSNV%7EVowrcRZwlP-j3750nk2rV1X6aA8pxQ7ffkF-BuSg9YHHfMnKVvImK%7E8q%7EeB1XCYhYWz1rc66Sa9PntcVu52DbQ6Ia-phKP-hGfAgrbeuwOeAmo-3gG0Zrc7TeLMmB-XO0alXI9CpKDj4-1WsNEFyH3aBSOf3aOJ8GDSTWD2A__&Key-Pair-Id=K6UGZS9ZTDSZM
18eecca14a21e86e0872638b00b610c1
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/evaluation-of-the-impact-of-the-biofield-energy-treated-test-formulation-on-various-biomarkers-in-human-bones-heart-liver-lungs-and-brain-cells/">https://www.trivedieffect.com/science/evaluation-of-the-impact-of-the-biofield-energy-treated-test-formulation-on-various-biomarkers-in-human-bones-heart-liver-lungs-and-brain-cells/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Vital organs dysfunctions are the major concern for human health worldwide. The study aim was to investigate the impact of Biofield Treated test formulation on vital organs function using cell-based assays. The test formulation/test item (TI) and cell media (Med) was divided into two parts; one untreated (UT) and other part received the Biofield Treatment remotely by a renowned Biofield Energy Healer, Victoria Lee Vannes, USA and was labeled as Biofield Treated (BT) test formulation/media. Based on the cell viability test formulation was found safe in six different cells. The test formulation groups showed 112.6% and 108.65% restoration of cell viability in human cardiac fibroblasts cells (HCF); while, 845.63% restoration of cell viability in human hepatoma cells (HepG2) compared to UT-Med + UT-TI group. Furthermore, 131.86% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) than untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.87%, 99.06%, and 105.13% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) than untreated. Additionally, ALP level was significantly increased by 150.97%, 382.08%, and 471.4% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) than untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 115.1% (1 µg/mL) and 165.77% (10 µg/mL)in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 117.65% (1 µg/mL) and 91.3% (63 µg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 40.56% in UT-Med + BT-TI at 10 µg/mL than untreated. Serotonin level was significantly increased by 543.84% (1 µg/mL), 477.12% (10 µg/mL), and 457.22% (10 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively than untreated. The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 186.96%, 341.43%, and 291.31% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 1 µg/mL than untreated. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Therefore, the Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Victoria Lee Vannes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Publisher
An entity responsible for making the resource available
SMGroup
Date
A point or period of time associated with an event in the lifecycle of the resource
19 July, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/704653c421d8cdcd1e5efb10d1ee6a70.pdf?Expires=1712793600&Signature=UyPN7ddUaM8mVrOkts1tMZ0tLJl8SxjBJrKdyYi9s520Fx37UhSNNJBxZvJ0jUwVUZAtk6RV8Jp5KEZVHGVzPkWy-U5zNYVzzhheIYP8L3h3tw7YBH87gEzpx01hmLOqQTwAr-0JZEAkoZbTMMAAITrFC55ypRepf1wfolovink9X4VMccXR3%7EkLim0BFNsRtAakoJgkFAzjWjnbW3e25kCTN7Fn5FAEVQHlYliRxdTFrplyPzcfzjx1pLuymAP-IXXnCTvxDrsmFunJDG6jVpqAw-fWa4VZC1jIfnfKFdhqW%7EBPPymWVq7GzTaEhlaPXho0ulBXn-IlBKwqtKeVeA__&Key-Pair-Id=K6UGZS9ZTDSZM
d2f0f6c5f9724110e2fc81625a541f1f
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/impact-of-the-biofield-energy-healing-based-test-formulation-on-various-health-biomarkers-using-cell-based-assays/">https://www.trivedieffect.com/science/impact-of-the-biofield-energy-healing-based-test-formulation-on-various-health-biomarkers-using-cell-based-assays/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Impact of the Biofield Energy Healing Based Test Formulation on Various Health Biomarkers Using Cell-Based Assays
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Various complementary approaches have been used against multiple organ dysfunction syndrome (MODS), which is the major contributor in high mortality among the healthcare centers. The aim of the present study was to determine the impact of the Biofield Energy Treatment on test formulation and different cell line medium related with vital organs functioning. Different organ based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Elizabeth Patric, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 84.9% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 308.1% at 0.1 µg/mL in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 166.8%, 266.4%, and 153.3% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Elizabeth Patric, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Publisher
An entity responsible for making the resource available
Annex Publishers
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Cardiac health
Liver health
Lungs health
Multiple organ failure
Organ health
The Trivedi Effect®
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/54a14b00575c4ecac35db30a82efc04f.pdf?Expires=1712793600&Signature=GgjRY8p-LFVZWfRaBNFaUtpUQPRAKXGyHL2oHH7O5LpnuFLPvBvmgu46AQ7Yeg9yfDcxIBsfpQ4pTtkOS2O8lqOl3qqR1J1dU8UTPmXVcSLTVNse9v5L2Z3dO4IRdl7CPQzNiqYaGQ3II0qRB7ApcihqiiCE9h8ER0tCjM6dOiyqhJwlHlJX01CRyoAoALgwJVi0rO81oSaXBXuRw4nvhPioLuT52D3-kR9ouuQXZhqTNMQGzUd0xOicvHUzZmxvzy-3WJN-3Aq4uJCNXMY7pVSAjAUzKC-pTDU9LSEay9fE0c4dgM5eRvNUgIMJ7ovrjTe0sJkHUZG5F7NOYn81Xw__&Key-Pair-Id=K6UGZS9ZTDSZM
760591f6ca379c8ce48002adeb16606b
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/impact-of-biofield-energy-treatment-based-test-formulation-on-vital-organ-health-specific-biomarkers-using-cell-line-study/">https://www.trivedieffect.com/science/impact-of-biofield-energy-treatment-based-test-formulation-on-vital-organ-health-specific-biomarkers-using-cell-line-study/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Multiple organ dysfunction syndrome or failure is one of the major concerns against healthcare services in order to maintain the normal function. The present study aimed to explore the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts, one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Ariadne Esmene Afaganis, Canada and was labeled as the Biofield Treated (BT) test formulation/media. The test formulation was tested for cell viability, and the data suggested that the test formulation was found safe and non-toxic against all the cell lines. Cytoprotective activity among the experimental groups showed a significant improved activity by 94.4% at 1 µg/mL in untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) group in human cardiac fibroblasts cells (HCF) cells, while 84.4% at 10 µg/mL in BT-Med + BT-TI groups in human hepatoma cells (HepG2), and 124% increased cytoprotective action at 1 µg/mL in UT-Med + BT-TI group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. ALP activity in MG-63 cells was significantly increased by 85.9% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 59.2% at 0.1 µg/mL in BT-Med + BT-TI groups as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 53% and 40.5% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 68.5%, 70.7%, and 16.8% at 0.1, 1, and 10 µg/mL respectively, and 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 33.5%, 63.2%, and 99.2% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by increased by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated group. Serotonin level was significantly increased by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 159.1% (at 50 µg/mL), 212.7% (at 1 µg/mL), and 278.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the present data concluded that the overall multiple organ health using various standard biomarkers in specific cell lines were significantly improved with respect to health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). Thus, it can be used as a complementary and alternative therapy approach against many multiple organ disorders such as coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Ariadne Esmene Afaganis, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Source
A related resource from which the described resource is derived
<a href="https://openaccesspub.org/jtrr/article/1131#idm1843080236">https://openaccesspub.org/jtrr/article/1131#idm1843080236</a>
Publisher
An entity responsible for making the resource available
Open Access Pub
Date
A point or period of time associated with an event in the lifecycle of the resource
Jul 13, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Identifier
An unambiguous reference to the resource within a given context
10.14302/issn.2640-6403.jtrr-19-2946
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptors
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/a7370f0b89e51f516d5feee476d9897d.pdf?Expires=1712793600&Signature=f%7EONgDiNqQ2Vp2nFSD%7ExclCBBCSH2PUXP1KS9w5v5tzu5JWoP1BECwLtaahXDHJtE4Q8hATv21mLbXwnhPyizVdt4X4EfRHNXbQFEHAh52jmy4wVtJRWgm9Wn3w%7Ezd3RSg8ApNiMEZ6YJKNo5ds-j7vbmXaLglZZRqSDKEfoorYA2HX9JeLGUnjevuh8a-K2at4knoDq6tagNf-6wuoLXS0MxW6Xv09IIizEuioMrCpbB7U1HZ2HQAjKtm58QAw2oBWBrjn10qCrlc5UExtCE41kA7e7bRTzU0EZndw22rQrNi1HMUMBm9BIX6UEgos3kFzkWxjycNy4TbFQwxmd6w__&Key-Pair-Id=K6UGZS9ZTDSZM
96339ca71005a2e7bbbee98d688e3c08
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/biofield-energy-treatment-based-test-formulation-as-a-novel-and-efficient-approach-on-various-biomarkers-in-human-bones-heart-liver-lungs-and-brain-cells/">https://www.trivedieffect.com/science/biofield-energy-treatment-based-test-formulation-as-a-novel-and-efficient-approach-on-various-biomarkers-in-human-bones-heart-liver-lungs-and-brain-cells/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Biofield Energy Treatment Based Test Formulation as a Novel and Efficient Approach on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Multiple organ dysfunction syndromes (MODS) are one of the common reasons for increased mortality rate against healthcare services. The present experiment aimed to determine the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Laura Nelson Streicher, and USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay. The test formulation was tested for cell viability, and the results showed that the test formulation was found non-toxic against all the cell lines at the tested concentrations. Cytoprotective activity among the experimental groups showed a significant improved activity by 156.9% at 1 µg/mL in UT- medium (Med) + BT - test item/formulation (TI) group in human cardiac fibroblasts cells (HCF) cells, while 94.5% at 25.5 µg/mL in the UT-Med + BT-TI group in human hepatoma cells (HepG2), and 92.4% at 63.75 µg/mL in the BT-Med + BT-TI group as compared with the untreated test group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. Alkaline phosphatase (ALP) activity in MG-63 cells was significantly increased by 80.2% and 93.5% at 10 and 50 µg/mL respectively in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 51.5% at 1 µg/mL in UT-Med + BT-TI group as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of lactate dehydrogenase-LDH activity) was significantly increased by 156.9% and 18.3% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 24.5% and 17.7% at10 and 25.5 µg/mL respectively, and 67.1%, 32.2%, 47.7%, and 73.1% improved cellular protection 1, 10, 25.5, and 63.75 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 93.1% and 64.1% at 1 µg/mL in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively as compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of superoxide dismutase-SOD activity) in terms of percentage was increased by 20.6% (at 0.1 µg/mL) and 6.9% (at 10 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 59.3% (at 10 µg/mL), 55.6% (at 1 µg/mL), and 100.1% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 150.6% (at 50 µg/mL), 380.1% (at 10 µg/mL), and 148.1% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, test formulation would be significantly useful for multiple organ health and improve overall health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). As a complementary and alternative therapy, Biofield Energy approach can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Laura Nelson Streicher, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Publisher
An entity responsible for making the resource available
Medwin Publishers
Date
A point or period of time associated with an event in the lifecycle of the resource
July 5, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Identifier
An unambiguous reference to the resource within a given context
10.23880/oajpr-16000180
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptors
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/86dc731cc3d614aaa97a605c9e321648.pdf?Expires=1712793600&Signature=DKG0BFqiqO1QYjPTyHLocbDEf6pClxs0QjXXW0l0gQcdPMkoQKeDsXvxlaxMyVJCY5Y1aOLlzrgSW3ALImJ4yOfadHf8ebWh2mj55Y-W96-99L9Ar7zVw8wgsUMUrbDUKiiMMrPndIGOi3GkQGNhSfDBUGkzIf8F47fsNQIWhw1XZhhA%7E2NzRmLv6FSg93vDWk3Da7en3-n4TlQi9ldB32nUEhl2D7JKpnmgfWX8jnPkSjAx8Lr6EcQOdtqKrUM0Qr1ns-iaiWVUiy1y-tHd4ChXh7cGWzLBO2EP-QOsrrP9tFNOVYJacxPO%7E83ZH7-AEAs0hadExiM7hOJ9pqPZEA__&Key-Pair-Id=K6UGZS9ZTDSZM
db7ca1aa5768b14b3b544a3aafbda874
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/comprehensive-vital-organ-biomarkers-analysis-of-the-consciousness-energy-healing-based-novel-test-formulation-using-various-cell-lines/">https://www.trivedieffect.com/science/comprehensive-vital-organ-biomarkers-analysis-of-the-consciousness-energy-healing-based-novel-test-formulation-using-various-cell-lines/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Comprehensive Vital Organ Biomarkers Analysis of the Consciousness Energy Healing Based Novel Test Formulation Using Various Cell-lines
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">The aim was to study the effect of the Consciousness Energy Treated test formulation on vital organ functions viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Alan Joseph Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was found as safe and non-toxic in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Energy Treated Test Item (BT-TI) group showed 181% and 82.2% restoration of cell viability at 1 and 10 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. The UT-Med + BT-TI group showed 126.8% and 86.3% restoration of cell viability at 10 and 25 µg/mL, respectively with respect to the untreated group in human hepatoma cells (HepG2). Furthermore, 101.2% (at 10 µg/mL), 103.6% (at 10 µg/mL) and 135% (at 25 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 90%, 87.3% and 86.9% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 137% in the BT-Med + UT-TI group in human endometrial adenocarcinoma cells (Ishikawa) at 1 µg/mL compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 52.1%, 65.9% and 63.5% at 1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 157% and 58.9% at 0.1 and 10 µg/mL, respectively in the BT-Med + BT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 168% and 135.4% in the UT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while, 137% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Serotonin level was significantly increased by 50.8% (at 63 µg/mL), 78.8% (at 63 µg/mL) and 52.7% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 265.5% (at 0.1 µg/mL) and 253.4% (at 1 µg/mL) in the UT-Med + BT-TI group; while 335.3% (at 0.1 µg/mL) in the BT-Med + BT-TI group compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Alan Joseph Balmer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Source
A related resource from which the described resource is derived
<a href="http://www.scitcentral.com/article.php?journal=43&article=778">http://www.scitcentral.com/article.php?journal=43&article=778</a>
Publisher
An entity responsible for making the resource available
SciTech Central Inc.
Date
A point or period of time associated with an event in the lifecycle of the resource
June 15, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/6b1deb7f09efa91809490aafbd576120.pdf?Expires=1712793600&Signature=jJ5fHihZhfKGDxhpvW58nmds9EHBt51YXJmAO78DGnNZYJdwLJo6m2Yu00iPX1ubBsl29m9iy54Qo%7E-BJkE53Nm1kJr%7EVF6iZMdf08WHq8cez8MXMCnMM%7E-SKGLZvg7Xk%7EdKhpENpQbN2aP0F81-tzP3F1WZz%7EUYjsgI4vepcSCX8e9EcCwEOqFarRppGdjHF9zXwnmBYV9QoL33k1rHMIkD-xA1%7EVTUAYEE1sFqPSO4D5VUuPxZ4hXdir8aHKsFyYSJOdwOiE4HEeHAkxVMPe7iidEqzb1zbfkKZUxsrTfscMBwqmIASbKTd37nNhfn-jKI2DtfZIo6OX3tAI8lGA__&Key-Pair-Id=K6UGZS9ZTDSZM
6511cf289d7e1a393e9f99a777e33927
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/protective-role-of-the-biofield-energy-treated-test-formulation-on-vitalorgans-function-using-cell-based-assays/">https://www.trivedieffect.com/science/protective-role-of-the-biofield-energy-treated-test-formulation-on-vitalorgans-function-using-cell-based-assays/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">Dysfunction of vital organs is the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Healing Treated test formulation on the function of vital organs in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Thomas Charles Slade, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like the untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) and BT-Med + BT-TI groups showed 74.4% (at 10 µg/mL) and 73.7% (at 1 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 76.4% (at 10 µg/mL) and 87.5% (at 1 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 209.5%, 757.8% and 836.2% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively, at 1 µg/mL compared to the untreated. Alkaline phosphatase (ALP) level was significantly increased by 71.7%, 71.9% and 56.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human bone osteosarcoma cells (MG-63) at 50 µg/mL compared to the untreated. Additionally, the level of ALP was also significantly increased by 124.9% and 106.3% in the BT-Med + BT-TI group at 25 and 50 µg/mL, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 88.3% and 75.5% in the BT-Med + BT-TI group at 1 and 10 µg/mL, respectively; while 82.8% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 47.5%, 79.8% and 94% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 67.4%, 60.8% and 80.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL; while 137% (at 0.1 µg/mL) in the BT-Med + BT-TI group as compared to the untreated group. Serotonin level was significantly increased by 225.7% (at 1 µg/mL), 176.1% (at 25 µg/mL) and 175.7% (at 63 µg/mL) in the BT-Med + BT-TI group; while 317.9% (at 1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 195.3% (at 1 µg/mL), 176.2% (at 10 µg/mL) and 194.7% (at 50 µg/mL) in the BT-Med + BT-TI group compared to the untreated group in MG-63 cells. Altogether data suggest that these results suggest that Biofield Energy Treated test formulation significantly protect the major organs viz. bones, heart, liver, lungs and brain and also improved their functions. Therefore, The Biofield Energy Treatment (The Trivedi Effect®) can be used as a complementary and alternative therapy against several disorders such as heart attack, heart failure, coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, asthma, pneumonia, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.</p>
Creator
An entity primarily responsible for making the resource
Thomas Charles Slade, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Source
A related resource from which the described resource is derived
<a href="http://www.scitcentral.com/article.php?journal=29&article=861">http://www.scitcentral.com/article.php?journal=29&article=861</a>
Publisher
An entity responsible for making the resource available
SciTech Central Inc.
Date
A point or period of time associated with an event in the lifecycle of the resource
July 21, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Bone Health
Brain health
Cardiac health
Consciousness Energy Healing
Liver health
Lungs health
The Trivedi Effect®
VDR receptor
-
https://d1y502jg6fpugt.cloudfront.net/25425/archive/files/b7a5c34b1d321b09201c1ad17676d57b.pdf?Expires=1712793600&Signature=vnNpMnDqYK8hElwwP-4D0KgGgCC%7EneAg1MTUX87wAJf6EGpnrcxQ%7Eejee0f2vxAUPiwSBXjJ2TxZ5rbvJ81pBoR1umm718zweyFvtYQSxPNIARoi7BoVZszZMsVHt5Oy63yHqHUt7-YbVfVioDVHyXeYsiCTHPY%7Ej5x2e59k3Ox12M2uu3mQlVjdVhdSZOF-inBqb8Ie3DXFA98iZlIF%7Ewt9yBqkUFQ-9IwOdn4Dn1WAmMLOOU-a3cydABlf0aBVPu7NEK%7EnbYMnGfxttBRrc0GwsHspIV578xODEFpdTIpzJbrlWu2-eorQZCUDMgW229PXtqoI-1TFSAbcUvnwdg__&Key-Pair-Id=K6UGZS9ZTDSZM
e79b5486efbe3af2e553363b63f56743
Website
A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ).
Local URL
The URL of the local directory containing all assets of the website
<a href="https://www.trivedieffect.com/science/evaluation-of-the-biofield-energy-treated-novel-testformulation-on-overall-organs-health-specific-biomarkers/">https://www.trivedieffect.com/science/evaluation-of-the-biofield-energy-treated-novel-testformulation-on-overall-organs-health-specific-biomarkers/</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evaluation of the Biofield Energy Treated Novel Test Formulation on Overall Organs Health Specific Biomarkers
Subject
The topic of the resource
Organ Health
Description
An account of the resource
<p style="text-align:justify;">The aim was to study the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, John Suzuki, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 91.6%, 56.9%, and 114.5% restoration of cell viability at 1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, BT-Med + BT-TI group showed 70.6%, 126.3%, and 60.2% restoration of cell viability at 1, 25, and 63 µg/mL, respectively; while 78.5% in the UT-Med + BT-TI group in human hepatoma cells (HepG2) compared to untreated. Furthermore, 72.6% (at 0.1 µg/mL), 57.4% (at 25 µg/mL), and 90.4% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + UT-TI, UT-Med + BT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 82.2% and 106.6% in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively at 10 µg/mL; while 80.2% (at 10 µg/mL) in the BT-Med + BT-TI group in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 90.2% (at 0.1 µg/mL) and 78.3% (at 10µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 63.7%, 59.6%, and 63.3% at 1, 10, and 25 µg/mL, respectively in the BT-Med + BT-TI group; while 122.2% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 62.8% and 153.2% at 1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 133.1%, 153.8%, and 107.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to untreated. Serotonin level was significantly increased by 75.7% (at 10 µg/mL), 124.1% (at 10 µg/mL), and 73.5% (at 10 µg/mL) in the BT-Med + UT-TI group at 10, 25, and 63 µg/mL, respectively; while 107.7% (at 25 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 162.2% (at 10 µg/mL), 193.3% (at 1 µg/mL), and 148.7% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.</p>
Creator
An entity primarily responsible for making the resource
John Suzuki, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Publisher
An entity responsible for making the resource available
Chembio Publishers
Date
A point or period of time associated with an event in the lifecycle of the resource
June 25, 2019
Language
A language of the resource
English
Type
The nature or genre of the resource
Journal Article
Biofield Energy Treatment
Bone Health
Brain health
Cardiac health
Lungs health
The Trivedi Effect®
VDR receptor